Search Results
Your search for Blood matches 4802 pages
Showing 1401 - 1450Inequities in Breast Cancer Screening During the COVID-19 Pandemic
Breast cancer screening took a sizeable hit during the COVID-19 pandemic, according to new research showing that the number of screening mammograms completed in a large group of women living in Washington state plummeted by nearly half. Published by Amram et al in JAMA Network Open, the study...
Drive, Curiosity, and a Love of Science: One Nurse’s Road to a Leadership Role in Oncology
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Deborah Watkins Bruner, RN, PhD, FAAN, noted for her work in patient-reported outcomes, symptom management, and comparative effectiveness of radiotherapy modalities. Her current research is focused on...
Oral Azacitidine Improves Overall Survival vs Placebo as Maintenance Therapy for AML in First Remission
As reported in The New England Journal of Medicine by Andrew H. Wei, MB, BS, PhD, of the Australian Centre for Blood Diseases, Monash University, Melbourne, and colleagues, the phase III QUAZAR AML-001 trial has shown prolonged overall survival with oral azacitidine maintenance therapy vs placebo...
Pembrolizumab as Long-Term Treatment Option in Relapsed or Refractory Classical Hodgkin Lymphoma
For patients with relapsed or refractory classic Hodgkin lymphoma (HL), salvage chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT) is the standard of care and can induce long-term remissions in at least 60% of patients.1,2 Patients with progression of disease after...
Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 26, 2021, the peptide-conjugated alkylating...
Oncolytic Virotherapy Achieves Early Signs of Success in High-Grade Gliomas
Treatment with genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) G207 alone or with radiation resulted in encouraging outcomes in a small study of pediatric patients with high-grade glioma. In a phase I trial, responses were observed in 11 of 12 children, and median overall...
Maintenance Rucaparib in Patients With Platinum-Sensitive Pancreatic Cancer and Germline or Somatic BRCA1, BRCA2, or PALB2 Variants
In a single-institution phase II study reported in the Journal of Clinical Oncology, Kim A. Reiss, MD, and colleagues found that maintenance treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib produced responses and was associated with good progression-free survival in...
Surveillance Protocol and Early Cancer Detection in Patients With Constitutional Mismatch Repair Deficiency Syndrome
As reported in the Journal of Clinical Oncology by Durno et al in the International Replication Repair Deficiency Consortium (IRRDC), use of an IRRDC surveillance protocol was associated with improved overall survival among patients with constitutional mismatch repair deficiency syndrome (CMMRD)....
How MRD Assessment May Help Guide Treatment Selection for Patients With AML
Complete morphologic remission is considered the first requirement for achieving long-term, leukemia-free survival and a potential cure in patients with acute leukemia, including acute myeloid leukemia (AML), and is the goal of all therapeutic strategies to date. Recognizing that the majority of...
What You Need to Know About Cancer and the Coronavirus
As a three-time breast cancer survivor, when the COVID-19 pandemic hit the United States this past January, I knew I had to do everything I could to avoid getting the virus. A host of lingering side effects from my surgeries, chemotherapy, and radiation treatments have left me with cardiovascular...
Bispecific Antibody Platform: Early Data in Relapsed and Refractory Myeloma
“There was never a night or a problem that could defeat sunrise or hope.” —Bernard Williams To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting...
Maryam Lustberg, MD, MPH, Accepts Leadership Roles at Smilow Cancer Hospital, Yale Cancer Center
Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as Associate Professor of Medicine (Medical Oncology). Dr. Lustberg joins Yale from...
Shared Risk Factors for Preventing Cancer and Cardiovascular Disease: The Evolving Focus of Cardio-oncology
Cardio-oncology represents the intersection of cancer and cardiovascular disease. Cancer therapies can result in cardiovascular complications, and some patients become less attentive to their chronic disease management after a diagnosis of cancer. As cancer patients are living longer, for some,...
Are Prevalent Cardiovascular Risk Factors Associated With Increased Risk of Subsequent Cancer?
In a study reported in JACC: CardioOncology, Emily S. Lau, MD, of the Cardiology Division, Department of Medicine, Massachusetts General Hospital, and colleagues found that the presence of cardiovascular disease (CVD) risk factors was significantly associated with an increased risk of future...
Virtual Meetings Are Here to Stay
In 2020, the 8th Annual Beirut Breast Cancer Conference (BBCC) was our last in-person meeting. The first cases of COVID-19 started in Lebanon around the end of February 2020, and the pandemic continues into its second year, with waves of rising cases following superspreader events and other likely...
Study Explores Racial Disparities in Renal Cell Carcinoma by Stage and Mortality
Research recently published by Valencia et al in the journal Cancers found that advanced-stage kidney cancer is more common in Hispanic American and Native American patients than in non-Hispanic White patients. Using data from the National Cancer Database and the Arizona Cancer Registry,...
Prospective Study Explores Prostate Cancer and Treatment Outcomes By Race
A study designed to enroll an equal number of Black and White men with advanced prostate cancer confirmed key findings that have been evident in retrospective analyses and suggest potential new avenues for treating Black patients who disproportionately die of the disease. Researchers at Duke Cancer ...
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Posttransplant Cyclophosphamide
In a National Marrow Donor Program–sponsored phase II trial reported in the Journal of Clinical Oncology, Shaw et al found that a strategy of bone marrow hematopoietic cell transplant (HCT) from mismatched unrelated donors using posttransplant cyclophosphamide in patients with hematologic...
Expanding Role of Liquid Biopsies in Cancer Detection and Therapeutics: Now and in the Near Future
“It is possible that within the next several years, perhaps 75% of cancers can be detected by screening,” Bert Vogelstein, MD, PhD, projected at the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer Care.1 “I anticipate that perhaps 50% of cancers can be detected...
Imaging Study Aims to Detect Rates of Cancer in Medieval Britain
The first study to use x-rays and computed tomography (CT) to detect evidence of cancer among the skeletal remains of a preindustrial population suggests that between 9% to 14% of adults in medieval Britain had the disease at the time of their death. These findings were published by Mitchell et al...
One vs Two Doses of the BNT162b2 COVID-19 Vaccine in Patients With Cancer: Immunogenicity and Efficacy
In an interim analysis of a prospective observational study reported in The Lancet Oncology, Monin et al found that a single dose of the BNT162b2 Pfizer–BioNTech COVID-19 vaccine was poorly immunogenic in patients with cancer, with immunogenicity markedly improving at 2 weeks after a second dose...
Antiviral T Cells for BK Virus–Associated Hemorrhagic Cystitis
A phase II trial has found found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis, a painful complication that is common after allogeneic stem cell transplants for patients with leukemia or lymphoma. ...
Umbralisib for Previously Treated Relapsed or Refractory Marginal Zone Lymphoma and Follicular Lymphoma
On February 5, 2021, umbralisib was granted accelerated approval for the following indications: adult patients with relapsed or refractory marginal zone lymphoma who have received at least one prior anti–CD20-based regimen and adult patients with relapsed or refractory follicular lymphoma who have...
Anti-BCMA–Directed CAR T-Cell Gene Therapy in Relapsed or Refractory Myeloma
"The noblest pleasure is the joy of understanding.” —Leonardo da Vinci To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel...
IMF Launches Initiative to Improve Outcomes in Multiple Myeloma Among Black Americans
The International Myeloma Foundation (IMF) has begun a multiyear, multidisciplinary initiative, M-Power Charlotte, which is designed to promote the early diagnosis and treatment of myeloma in the Black community. The IMF is working with Atrium Health Levine Cancer Institute’s Disparities &...
A Physician-Scientist’s Mother, Who Nursed Those With Chronic Diseases, Fueled His Passion for Biomedical Research
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Griffin P. Rodgers, MD, MACP, Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Dr. Rodgers, a physician-scientist,...
Sitagliptin Added to Tacrolimus/Sirolimus Prophylaxis Regimen for Acute Graft-vs-Host Disease After HSCT
In a phase II trial reported in The New England Journal of Medicine, Sherif S. Farag, MD, PhD, of Indiana University School of Medicine, and colleagues found that the addition of the dipeptidyl peptidase 4 (DPP-4; CD26) inhibitor sitagliptin to tacrolimus and sirolimus prophylaxis resulted in a low ...
Transmission of Cancer to Infants From Mothers With Cervical Cancer During Vaginal Delivery
In a brief report in The New England Journal of Medicine, Ayumu Arakawa, MD, of the Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, and colleagues described identification of lung cancer in two boys that likely resulted from transmission of maternal cervical cancer tumor...
Study Finds Tranexamic Acid Unable to Prevent Bleeding in Patients With Hematologic Malignancies
In the first randomized trial to evaluate prophylactic antifibrinolytic therapy in patients with hematologic malignancies, tranexamic acid failed to reduce bleeding or the need for transfusion vs placebo. The study was featured as a Plenary Session during the 2020 American Society of Hematology...
Study Explores Rates of Germline Mutations in Patients With Colorectal Cancer
In a recent study published by Uson Junior et al in Clinical Gastroenterology and Hepatology, researchers found one in six patients with colorectal cancer had an inherited cancer-related genetic mutation, which may be linked to a predisposition to the disease. In addition, the researchers...
Expert Point of View: Aaron T. Gerds, MD, MS
Aaron T. Gerds, MD, MS, Associate Professor of Medicine, Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute and Medical Director of the Case Comprehensive Cancer Center Clinical Research Office, found the MANIFEST-2 findings to be highly noteworthy. He cited a...
National Survey Finds Average-Risk Individuals Prefer Stool-Based Tests Over Colonoscopy for Colorectal Cancer Screening
A national survey conducted by Zhu et al to identify patient preferences among colorectal cancer screening modalities to improve population adherence to colorectal cancer screening has found, when presented with a choice, most individuals with an average risk of colorectal cancer prefer stool-based ...
MANIFEST-2: CPI-0610 Shows Benefit in Myelofibrosis
The novel targeted agent CPI-0610 enhanced responses to ruxolitinib in patients with myelofibrosis enrolled in the global phase II MANIFEST-2 trial, investigators reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.1,2 “Preliminary data demonstrate the...
Recent Studies Explore Efficacy of COVID-19 Vaccination in Patients With Leukemia and Myeloma
Two new studies published in the journal Blood suggest that the BNT162b2 mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma. According to researchers, these studies could help inform the ideal time for vaccination of these...
Certain Genetic Mutations May Increase Risk of Death From Infection in Patients With CLL
Death from infection—the leading cause of death for patients with chronic lymphocytic leukemia (CLL)—may be linked to specific gene mutations, according to results from a study published by Else et al in the journal Leukemia. Testing for these mutations could be used to identify patients at a...
Integration of Brentuximab Vedotin Into Front-Line Treatment for Pediatric Patients With High-Risk Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Metzger et al found that the integration of brentuximab vedotin into front-line treatment of pediatric patients with high-risk classical Hodgkin lymphoma resulted in avoidance of radiotherapy in many patients, as well as high rates of...
RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML
The novel agentSY-1425 combined with azacitidine appears to be active in retinoic acid receptor alpha (RARA) superenhancer–positive newly diagnosed and relapsed or refractory acute myeloid leukemia (AML), according to the results of a phase II trial presented at the 2020 American Society of...
Pediatric Patients With High-Grade Gliomas: Treatment With Oncolytic HSV-1 G207 Immunovirotherapy
In a phase I trial reported at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 (Abstract CT018) and simultaneously published in The New England Journal of Medicine, Friedman et al found that oncolytic virotherapy with genetically engineered herpes simplex virus-1...
Belzutifan Shows Activity in Advanced Renal Cell Carcinoma, Both as a Single Agent and in Combination Therapy
Separate studies presented at the 2021 Genitourinary Cancers Symposium provide supportive evidence for belzutifan (formerly MK-6482) as an active treatment for metastatic clear cell renal cell carcinoma (RCC). One study showed single-agent activity for this novel approach in an early-phase trial,...
Unselected Autologous Tumor-Infiltrating Lymphocyte Therapy for Metastatic Cutaneous Melanoma
Treatment with unselected autologous tumor-infiltrating lymphocytes (TILs) showed early clinical efficacy among patients with advanced melanoma, according to results presented by Hawkins et al during week 1 of the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 (Abstract ...
Novel Insights in Myelodysplastic Syndromes: Highlights From 2020 ASH Meeting
To complement The ASCO Post’s comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel clinical trial findings in myelodysplastic syndromes (MDS). For full details of...
Johan Vansteenkiste, MD, PhD, and Fiona Blackhall, PhD, FRCP, Honored for Lung Cancer Research by ESMO and IASLC
The European Society for Medical Oncology and the International Association for the Study of Lung Cancer recently presented the Heine H. Hansen Award 2021 to Johan Vansteenkiste, MD, PhD, Professor of Medicine at the Catholic University of Leuven and Head of Clinic in the Respiratory Oncology Unit...
Cardiovascular Concerns With the Use of VEGFR Tyrosine Kinase Inhibitors
Tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor (VEGFR) have proved to be effective drugs in the treatment of many solid tumors. However, their clinical benefit may come at the cost of cardiovascular toxicity if clinicians are not vigilant and proactive. During...
Second-Line FOLFOX vs Active Symptom Control in Advanced Biliary Tract Cancer
In the phase III ABC-06 trial reported in The Lancet Oncology, Angela Lamarca, PhD, and colleagues found that second-line FOLFOX (leucovorin, fluorouracil [5-FU], and oxaliplatin) produced a statistically significant improvement in median overall survival vs active symptom control in patients with...
Cardiovascular Disease in Hematologic Malignancies: Who Is at Risk?
Given the improvements in diagnostic strategies, treatment, and supportive care, long-term survival is now an expected outcome for a large majority of patients with hematologic malignancies. Unfortunately, radiation therapy and anthracyclines, which form the backbone of front-line treatment, have...
Oral Azacitidine in Lower-Risk Myelodysplastic Syndromes
In a phase III trial reported in the Journal of Clinical Oncology, Guillermo Garcia-Manero, MD, and colleagues found that oral azacitidine significantly improved red blood cell (RBC) transfusion independence vs placebo in patients with lower-risk myelodysplastic syndromes. An increase in early...
Diet and Exercise Intervention May Increase Efficacy of Chemotherapy in Pediatric Patients With Leukemia
Research published by Orgel et al in the journal Blood Advances showed that restricting calories, reducing fat and sugar intake, and increasing physical activity may boost the effectiveness of chemotherapy for older children and adolescents with leukemia. This intervention, which improved...
Improving Survival for Patients With Stage II Pancreatic Cancer: Chemotherapy Followed by Resection
Patients with stage II pancreatic cancer who are treated with chemotherapy followed by resection live nearly twice as long as patients who receive only chemotherapy, according to a recent study published by Amanda K. Arrington, MD, MHM, FACS, and colleagues in the Journal of the American College of ...
Role of Whole-Genome Sequencing in Identifying Patients With MGUS at Risk of Progression to Multiple Myeloma
A study published by Oben et al in Nature Communications has shown that whole-genome sequencing can help determine which patients with a multiple myeloma precursor condition known as monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma may be at risk for progression to...
Addition of Pegaspargase Intensification to Standard Low-Intensity Chemotherapy Backbone in Pediatric Low-Risk B-Cell ALL
In an analysis from the Children’s Oncology Group (COG) AALL0331 trial reported in the Journal of Clinical Oncology, Mattano et al found that the addition of pegaspargase intensification did not improve the high rate of continuous complete remission achieved with a standard COG low-intensity...
